The ongoing multicentric international trial NoLEEta led by French Breast Cancer Intergroup UNICANCER has the same purpose by aiming to compare two patient study arms, one treated with chemotherapy followed by CDK4/6 inhibition and endocrine therapy and another treated with CDK4/6 inhibitors and endocrine therapy but without chemotherapy [119]. Here, CDK4 is linked to breast carcinoma.